Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Clinical trial NCT04215159 · UNKNOWN

Trial details

NCT number: NCT04215159
Sponsor: Jin-Hee Ahn
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

HER-2 Protein Overexpression HER-2 Gene Amplification

Start date: 2019-12-30
Primary completion: 2019-12-30
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.